Clinical trial
A Multi-centre Phase II Randomized-controlled Study on Addition of Durvalumab (MEDI4736) to Induction Chemotherapy and Concurrent Chemoradiation and Followed by Maintenance Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT04447612 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centre Phase II Randomized-controlled Study on Addition of Durvalumab (MEDI4736) to Induction Chemotherapy and Concurrent Chemoradiation and Followed by Maintenance Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
- Lead sponsor
- The University of Hong Kong
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 1, 2020
- Completion date
- December 31, 2024
- Enrollment
- 118 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.